---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016779"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:59:03.685162+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027

## Summary
- Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.
- NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.
- Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.
- NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers.

## SEC filing metadata
- accession: 0001104659-25-016779
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/0001104659-25-016779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/tm257439d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016779
- JSON: https://secwatch.observer/filing/0001104659-25-016779.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.